Laboratorios Farmaceuticos Rovi, S.A. Share Price
Stocks
ROVI
ES0157261019
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
04:22:31 04/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 63.58 EUR | +0.59% |
|
+3.59% | - |
| 05/10 | Spanish stocks - Factors to watch on Oct 5 | RE |
| 23/07 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 |
| Market Cap | 323.22Cr 361.79Cr 296.9Cr 269.65Cr 506.37Cr 34TCr 519.1Cr 3.54TCr 1.43TCr 18TCr 1.36TCr 1.33TCr 57TCr | P/E 2026 * |
20x | P/E 2027 * | 19.1x |
|---|---|---|---|---|---|
| Enterprise Value | 322.78Cr 361.3Cr 296.49Cr 269.28Cr 505.68Cr 34TCr 518.39Cr 3.54TCr 1.42TCr 18TCr 1.36TCr 1.33TCr 57TCr | EV / Sales 2026 * |
4.14x | EV / Sales 2027 * | 3.56x |
| Free-Float |
31.63% | Yield 2026 * |
1.5% | Yield 2027 * | 1.87% |
| Markets | Quality | ||
|---|---|---|---|
BME
| ROVI | Delayed | |
CBOE
| ROVIe | Real-time | |
|
Tradegate
| 41L | Real-time | |
|
Deutsche Boerse AG
| 41L | Delayed | |
|
CBOE
| 0ILL | Real-time | |
|
Börse Stuttgart
| 41L | Delayed | |
|
Boerse Muenchen
| 41L | Real-time | |
|
Wiener Boerse
| ROVI | End-of-day quote | |
|
Borsa Italiana
| 1ROVI | End-of-day quote | |
|
Xetra
| 41L | Delayed |
Last Transcript: Laboratorios Farmaceuticos Rovi, S.A.
| 1 day | +0.55% | ||
| 1 week | +3.59% | ||
| Current month | +1.52% | ||
| 1 month | +11.31% | ||
| 3 months | +7.72% | ||
| 6 months | -20.03% |
| 1 week | 59.35 |  | 63.95 |
| 1 month | 56.85 | | 63.95 |
| Current year | 53.1 | | 86.7 |
| 1 year | 53.1 | | 86.7 |
| 3 years | 45.52 | | 94.8 |
| 5 years | 35.2 | | 94.8 |
| 10 years | 10.8 | | 94.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 27/07/2007 | |
| Director of Finance/CFO | - | 01/01/2001 | |
| Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | 17/07/2021 | |
| Director/Board Member | - | 27/07/2007 | |
| Director/Board Member | - | 27/07/2007 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 23/06/23 | Buy | Director | 1,000 | 0.0019% | ||
| 13/04/22 | Norbel Inversiones SL
| Sell | Company | 5,60,690 | 1.0000% | |
| 15/03/22 | Norbel Inversiones SL
| Sell | Company | 28,03,448 | 5.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.59% | +3.59% | +7.81% | +33.24% | 361.79Cr | |
| -0.11% | +9.94% | +57.20% | +148.21% | 1,25500Cr | |
| -1.62% | -0.95% | +42.90% | +75.88% | 64TCr | |
| -0.98% | -0.14% | +34.93% | +102.23% | 51TCr | |
| -0.06% | -2.16% | +47.80% | +64.54% | 38TCr | |
| -2.49% | +2.01% | +75.38% | +39.94% | 36TCr | |
| +0.75% | +2.49% | +30.51% | +57.22% | 30TCr | |
| -0.62% | +7.16% | +9.18% | +33.11% | 29TCr | |
| -0.90% | +2.97% | +55.67% | +70.93% | 25TCr | |
| -1.68% | +5.27% | +37.21% | +105.26% | 21TCr | |
| Average | -0.22% | +2.85% | +39.86% | +73.05% | 41.89TCr | |
| Weighted average by Cap. | -0.05% | +3.90% | +46.69% | +93.50% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 78Cr 87Cr 72Cr 65Cr 122.25Cr 8.27TCr 125.32Cr 855.62Cr 344.19Cr 4.37TCr 327.85Cr 320.84Cr 14TCr | 90Cr 100.29Cr 82Cr 75Cr 140.37Cr 9.5TCr 143.89Cr 982.39Cr 395.19Cr 5.01TCr 376.43Cr 368.38Cr 16TCr |
| Net income | 15Cr 16Cr 13Cr 12Cr 23Cr 1.55TCr 23Cr 160.38Cr 65Cr 818.58Cr 61Cr 60Cr 2.59TCr | 17Cr 19Cr 16Cr 14Cr 27Cr 1.8TCr 27Cr 186.34Cr 75Cr 951.09Cr 71Cr 70Cr 3.01TCr |
| Net Debt | -44.28L -49.56L -40.67L -36.94L -69.37L -47Cr -71.11L -4.86Cr -1.95Cr -25Cr -1.86Cr -1.82Cr -79Cr | -4.29Cr -4.8Cr -3.94Cr -3.58Cr -6.72Cr -454.96Cr -6.89Cr -47Cr -19Cr -240.13Cr -18Cr -18Cr -761.1Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/26/04 | €63.50 | +0.47% | 24,339 |
| 03/26/03 | €63.20 | -0.16% | 1,01,175 |
| 02/26/02 | €63.30 | +1.20% | 97,719 |
| 30/26/30 | €62.55 | +1.62% | 1,12,412 |
| 29/26/29 | €61.55 | +0.41% | 76,647 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ROVI Stock
Select your edition
All financial news and data tailored to specific country editions
